Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial

The Lancet Diabetes & Endocrinology · Elsevier

Аннотация

Publication date: October 2026 Source: The Lancet Diabetes & Endocrinology, Volume 14, Issue 10 Author(s): Lixin Guo, Xiaolei Bao, Kuo-Chin Huang, Kristoffer Jensen Kolnes, Christian Laugesen, Yibing Lu, Bifen Luo, Guoyue Yuan, Robert F Kushner

Читать у издателя →

Похожие статьи